There are two anti-PD-1 agents, Nivolumab and Pembrolizumab and three anti-PD-L-1 agents, Atezolizumab, Avelumab, and Durvalumab, approved for the treatment of lymphomas. The gene discussed is CD274; the disease is lymphoma.